Supplementary Figure 1 from A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

Abstract

PDF file, 71KB, Best responses (maximum reduction in sum of longest diameter of target lesions from baseline) in individual patients.